About Innovus Pharmaceuticals (OTCMKTS:INNV)
Innovus Pharmaceuticals, Inc. is a pharmaceutical company engaged in the commercialization, licensing, and development of non-prescription medicine and consumer care products to improve men's and women's health and vitality and respiratory diseases. The Company markets approximately five products in the United States and six in a range of countries around the world through its commercial partners. It has commercial agreements in over 60 countries around the world through its commercial partners. Its marketed products include Zestra, EjectDelay, Sensum+, Zestra Glide, Vesele and Androferti. In addition, the Company has a pipeline of over three additional products, including FlutiCare Over-The-Counter (OTC) for Allergic Rhinitis; Urocis XR, an extended release of Vaccinium Marcocarpon (cranberry), and AndroVit, a supplement to support overall prostate and male sexual health, which is marketed in Europe.
Industry, Sector and Symbol
Trailing P/E RatioN/A
Forward P/E RatioN/A
Sales & Book Value
Annual Sales$4.82 million
Price / Sales5.29
Price / CashN/A
Book Value$0.01 per share
Price / Book15.50
Return on Equity-330.39%
Return on Assets-72.75%
Innovus Pharmaceuticals (OTCMKTS:INNV) Frequently Asked Questions
What is Innovus Pharmaceuticals' stock symbol?
Innovus Pharmaceuticals trades on the OTCMKTS under the ticker symbol "INNV."
How were Innovus Pharmaceuticals' earnings last quarter?
Innovus Pharmaceuticals Inc (OTCMKTS:INNV) issued its quarterly earnings data on Tuesday, November, 14th. The company reported ($0.01) EPS for the quarter. The company had revenue of $2.22 million for the quarter. Innovus Pharmaceuticals had a negative return on equity of 330.39% and a negative net margin of 102.95%. View Innovus Pharmaceuticals' Earnings History.
Who are some of Innovus Pharmaceuticals' key competitors?
Some companies that are related to Innovus Pharmaceuticals include IntelGenx Technologies (IGXT), Pain Therapeutics (PTIE), Celsion (CLSN), TRACON Pharmaceuticals (TCON), Immutep (IMMP), Acerus Pharmaceuti (TRLPF), Egalet (EGLT), Proteon Therapeutics (PRTO), Chiasma (CHMA), Cleveland BioLabs (CBLI), Soleno Therapeutics (SLNO), OvaScience (OVAS), Eleven Biotherapeutics (EBIO), AzurRx BioPharma (AZRX), Vical (VICL), Lipocine (LPCN), Evoke Pharma (EVOK) and Zosano Pharma (ZSAN).
Who are Innovus Pharmaceuticals' key executives?
Innovus Pharmaceuticals' management team includes the folowing people:
- Henry J. Esber Ph.D., Chairman of the Board (Age 78)
- Bassam B. Damaj Ph.D., President, Chief Executive Officer, Director (Age 48)
- Rauly Gutierrez CPA, Principal Financial Officer, Principal Accounting Officer
- Randy J. Berholtz Esq. J.D., Executive Vice President, General Counsel, Secretary (Age 53)
- Vivian H. Liu, Director (Age 55)
- Ziad Mirza M.D., Director (Age 54)
How do I buy Innovus Pharmaceuticals stock?
Shares of Innovus Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Innovus Pharmaceuticals' stock price today?
One share of Innovus Pharmaceuticals stock can currently be purchased for approximately $0.16.
How big of a company is Innovus Pharmaceuticals?
Innovus Pharmaceuticals has a market capitalization of $25.49 million and generates $4.82 million in revenue each year. The company earns $-13,700,000.00 in net income (profit) each year or ($0.07) on an earnings per share basis. Innovus Pharmaceuticals employs 5 workers across the globe.
How can I contact Innovus Pharmaceuticals?
Innovus Pharmaceuticals' mailing address is 8845 Rehco Road, San Diego CA, 92122. The company can be reached via phone at 858-964-5123 or via email at [email protected]
MarketBeat Community Rating for Innovus Pharmaceuticals (INNV)MarketBeat's community ratings are surveys of what our community members think about Innovus Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Innovus Pharmaceuticals (OTCMKTS:INNV) Analyst Ratings History
No equities research coverage for this company has been tracked by MarketBeat
Innovus Pharmaceuticals (OTCMKTS:INNV) Earnings History and Estimates Chart
Innovus Pharmaceuticals (OTCMKTS INNV) Earnings History by Quarter
(Earnings results data provided by Zacks Investment Research)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|11/14/2017||Q3 2017||($0.01)||$2.22 million||View||N/A|
|8/14/2017||Q2 2017||($0.01)||$2.04 million||View||N/A|
|5/12/2017||Q1 2017||($0.02)||$2.18 million||View||N/A|
|3/6/2017||Q4 2016||($0.02)||$1.69 million||View||N/A|
|11/10/2016||Q3 2016||($0.01)||$1.88 million||View||N/A|
|8/15/2016||Q2 2016||($0.05)||$1.02 million||View||N/A|
|5/16/2016||Q1 2016||($0.02)||$0.23 million||View||N/A|
Innovus Pharmaceuticals (OTCMKTS:INNV) Earnings Estimates
Current Year EPS Consensus Estimate: $-0.04 EPS
Dividend History for Innovus Pharmaceuticals (OTCMKTS:INNV)
No dividend announcements for this company have been tracked by MarketBeat.com
Innovus Pharmaceuticals (OTCMKTS INNV) News Headlines
Innovus Pharmaceuticals (OTCMKTS:INNV) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Financials are not available for this stock.
Innovus Pharmaceuticals (OTCMKTS INNV) Stock Chart for Sunday, March, 18, 2018